ILX651

DRUG3 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Hormone-refractory Prostate CancerMelanomaNon-Small-Cell Lung Carcinoma

Phase 2

Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma

CompletedNCT00068211

Genzyme, a Sanofi CompanyMelanoma

Start: 2003-08-31End: 2006-01-31Updated: 2015-03-05

Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

CompletedNCT00078455

Genzyme, a Sanofi CompanyNon-Small-Cell Lung Carcinoma

Start: 2003-12-31End: 2005-08-31Updated: 2015-03-05

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

CompletedNCT00082134

Genzyme, a Sanofi CompanyHormone-refractory Prostate Cancer

End: 2005-12-31Target: 40Updated: 2015-03-05